Kairos Pharma Ltd. (KAPA)

NYSE American: KAPA · Real-Time Price · USD

0.31

-0.01 (-3.13%)

At close: Aug 18, 2026, 8:00 PM

-3.13% (1D)

No data available

Bid	n/a
Market Cap	6.64M
Revenue (ttm)	n/a
Net Income (ttm)	-5.8M
Beta	n/a
EPS (ttm)	-0.27
PE Ratio (ttm)	n/a
Forward PE	-0.46
P/B (ttm)	1.02
P/S (ttm)	n/a
Earnings Date	n/a

Ask	n/a
Volume	207,272
Avg. Volume (20D)	2,194,508
Open	0.32
Previous Close	0.32
Day's Range	0.31 - 0.32
52-Week Range	0.27 - 2.11
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About KAPA

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, a...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 16, 2024

Employees 1

Stock Exchange NYSE American

Ticker Symbol KAPA

Website https://kairospharma.com

Full Company Profile

Financial Performance

In 2025, Kairos Pharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -5.45M, an increase of 109.26%.

Financial Statements

Earnings Surprise

Kairos Pharma has released their quarterly earnings on May 13, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.08 misses estimates by -0.01, with 0.00% YoY growth.

News

2 weeks ago · Simply Wall St.

Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News

Bayer’s share price has climbed sharply over the past year, yet the valuation checks still suggest the stock screens as cheap on several measures. This raises the question of how much of the recent op...

3 weeks ago · Simply Wall St.

Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health

Bayer announced two new collaborations, one with Kairos Pharma on a prostate cancer therapy and another with Henry Ford Health on wider research across several diseases. The Kairos Pharma partnership ...

1 month ago · Zacks

All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy

Kairos Pharma, Ltd. (KAPA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).